Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CNS and neurological disorder therapeutics - ACADIA

Next Previous
Drug Profile

Research programme: CNS and neurological disorder therapeutics - ACADIA

Alternative Names: AC-131; AC-186; ERβ programme - ACADIA; Estrogen receptor beta agonists - ACADIA; Nurr1 programme - ACADIA; Nurr1-retinoid X receptor agonists - ACADIA; Nurr1-RXR agonists - ACADIA

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Dopamine modulators; Estrogen receptor beta agonists; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists; Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top